← Eichor
Study identifier: NCT05836896 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies

Condition: Neoplasms · Relapsed Diffuse Large B-cell Lymphoma (DLBCL) · Refractory Diffuse Large B-cell Lymphoma (DLBCL)  ·  Sponsor: Technische Universität Dresden

PhasePhase 1
Planned participants16
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The purpose of this phase I study is to determine whether MDC-CAR-BCMA001 (BCMA directed CAR T-cells) is safe and tolerable in the treatment of relapsed and refractory B-cell malignancies

This description comes directly from the study's public registry record.

Talk to the study team

Martin Wermke, Prof.  ·  +49 351 458 13408  ·  carlotta@ukdd.de

Always discuss trial participation with your own doctor first.

Locations (1)

Technische Universität Dresden, NCT/UCC, Early Clinical Trial UnitDresden, GermanyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05836896